Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant Phase 2b in Refractory Chronic Cough
NCT02612610Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gefapixant in refractory chronic cough (RCC), unexplained chronic cough, sponsored by Merck & Co.. Started Dec 2015; status: completed.
02
Drugs
gefapixant
03
Conditions
refractory chronic cough (RCC)unexplained chronic cough
Beyond the preview
Go deeper on NCT02612610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612610.